{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T15:54:59Z","timestamp":1778687699993,"version":"3.51.4"},"reference-count":119,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,5,12]],"date-time":"2015-05-12T00:00:00Z","timestamp":1431388800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1136\/annrheumdis-2015-207524","type":"journal-article","created":{"date-parts":[[2015,5,13]],"date-time":"2015-05-13T02:31:28Z","timestamp":1431484288000},"page":"3-15","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1210,"title":["Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force"],"prefix":"10.1016","volume":"75","author":[{"given":"Josef S","family":"Smolen","sequence":"first","affiliation":[]},{"given":"Ferdinand C","family":"Breedveld","sequence":"additional","affiliation":[]},{"given":"Gerd R","family":"Burmester","sequence":"additional","affiliation":[]},{"given":"Vivian","family":"Bykerk","sequence":"additional","affiliation":[]},{"given":"Maxime","family":"Dougados","sequence":"additional","affiliation":[]},{"given":"Paul","family":"Emery","sequence":"additional","affiliation":[]},{"given":"Tore K","family":"Kvien","sequence":"additional","affiliation":[]},{"given":"M Victoria","family":"Navarro-Comp\u00e1n","sequence":"additional","affiliation":[]},{"given":"Susan","family":"Oliver","sequence":"additional","affiliation":[]},{"given":"Monika","family":"Schoels","sequence":"additional","affiliation":[]},{"given":"Marieke","family":"Scholte-Voshaar","sequence":"additional","affiliation":[]},{"given":"Tanja","family":"Stamm","sequence":"additional","affiliation":[]},{"given":"Michaela","family":"Stoffer","sequence":"additional","affiliation":[]},{"given":"Tsutomu","family":"Takeuchi","sequence":"additional","affiliation":[]},{"given":"Daniel","family":"Aletaha","sequence":"additional","affiliation":[]},{"given":"Jose Louis","family":"Andreu","sequence":"additional","affiliation":[]},{"given":"Martin","family":"Aringer","sequence":"additional","affiliation":[]},{"given":"Martin","family":"Bergman","sequence":"additional","affiliation":[]},{"given":"Neil","family":"Betteridge","sequence":"additional","affiliation":[]},{"given":"Hans","family":"Bijlsma","sequence":"additional","affiliation":[]},{"given":"Harald","family":"Burkhardt","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2731-9180","authenticated-orcid":false,"given":"Mario","family":"Cardiel","sequence":"additional","affiliation":[]},{"given":"Bernard","family":"Combe","sequence":"additional","affiliation":[]},{"given":"Patrick","family":"Durez","sequence":"additional","affiliation":[]},{"given":"Joao Eurico","family":"Fonseca","sequence":"additional","affiliation":[]},{"given":"Alan","family":"Gibofsky","sequence":"additional","affiliation":[]},{"given":"Juan J","family":"Gomez-Reino","sequence":"additional","affiliation":[]},{"given":"Winfried","family":"Graninger","sequence":"additional","affiliation":[]},{"given":"Pekka","family":"Hannonen","sequence":"additional","affiliation":[]},{"given":"Boulos","family":"Haraoui","sequence":"additional","affiliation":[]},{"given":"Marios","family":"Kouloumas","sequence":"additional","affiliation":[]},{"given":"Robert","family":"Landewe","sequence":"additional","affiliation":[]},{"given":"Emilio","family":"Martin-Mola","sequence":"additional","affiliation":[]},{"given":"Peter","family":"Nash","sequence":"additional","affiliation":[]},{"given":"Mikkel","family":"Ostergaard","sequence":"additional","affiliation":[]},{"given":"Andrew","family":"\u00d6st\u00f6r","sequence":"additional","affiliation":[]},{"given":"Pam","family":"Richards","sequence":"additional","affiliation":[]},{"given":"Tuulikki","family":"Sokka-Isler","sequence":"additional","affiliation":[]},{"given":"Carter","family":"Thorne","sequence":"additional","affiliation":[]},{"given":"Athanasios G","family":"Tzioufas","sequence":"additional","affiliation":[]},{"given":"Ronald","family":"van Vollenhoven","sequence":"additional","affiliation":[]},{"given":"Martinus","family":"de Wit","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5781-158X","authenticated-orcid":false,"given":"Desir\u00e9e","family":"van der Heijde","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1136\/annrheumdis-2015-207524_bib1","first-page":"579","article-title":"Development of a Disease activity score based on judgement in clinical practice by rheumatologists","volume":"20","author":"Van der Heijde","year":"1993","journal-title":"J Rheumatol"},{"key":"10.1136\/annrheumdis-2015-207524_bib2","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/art.1780380107","article-title":"Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis","volume":"38","author":"Prevoo","year":"1995","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2015-207524_bib3","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1093\/rheumatology\/keg072","article-title":"A simplified disease activity index for rheumatoid arthritis for use in clinical practice","volume":"42","author":"Smolen","year":"2003","journal-title":"Rheumatology"},{"key":"10.1136\/annrheumdis-2015-207524_bib4","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/art.1780380602","article-title":"American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis","volume":"38","author":"Felson","year":"1995","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2015-207524_bib5","doi-asserted-by":"crossref","first-page":"R796","DOI":"10.1186\/ar1740","article-title":"Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score","volume":"7","author":"Aletaha","year":"2005","journal-title":"Arthritis Res"},{"key":"10.1136\/annrheumdis-2015-207524_bib6","doi-asserted-by":"crossref","first-page":"699","DOI":"10.7326\/0003-4819-124-8-199604150-00001","article-title":"The effectiveness of early treatment with \u201csecond-line\u201d antirheumatic drugs. A randomized, controlled trial","volume":"124","author":"van der Heide","year":"1996","journal-title":"Ann Intern Med"},{"key":"10.1136\/annrheumdis-2015-207524_bib7","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/S0002-9343(01)00872-5","article-title":"Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies","volume":"111","author":"Lard","year":"2001","journal-title":"Am J Med"},{"key":"10.1136\/annrheumdis-2015-207524_bib8","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1093\/rheumatology\/keh199","article-title":"Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis","volume":"43","author":"Nell","year":"2004","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/annrheumdis-2015-207524_bib9","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1136\/ard.54.12.944","article-title":"Early rheumatoid arthritis: time to aim for remission?","volume":"54","author":"Emery","year":"1995","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2015-207524_bib10","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1136\/bmj.2.6150.1501-c","article-title":"Treatment of rheumatoid arthritis","volume":"2","author":"Luukkainen","year":"1978","journal-title":"Br Med J"},{"key":"10.1136\/annrheumdis-2015-207524_bib11","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1136\/ard.2008.090019","article-title":"Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and TNF-blockade","volume":"68","author":"Smolen","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2015-207524_bib12","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1136\/ard.2009.119156","article-title":"Repair of erosions occurs almost exclusively in damaged joints without swelling","volume":"69","author":"Lukas","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 31","key":"10.1136\/annrheumdis-2015-207524_bib13","first-page":"S178","article-title":"Methotrexate as the \u201canchor drug\u201d for the treatment of early rheumatoid arthritis","volume":"21","author":"Pincus","year":"2003","journal-title":"Clin Exp Rheumatol"},{"key":"10.1136\/annrheumdis-2015-207524_bib14","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1136\/ard.2008.092668","article-title":"Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature","volume":"68","author":"Visser","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2015-207524_bib15","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1002\/1529-0131(200107)44:7<1515::AID-ART273>3.0.CO;2-7","article-title":"Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study","volume":"44","author":"van Ede","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2015-207524_bib16","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0140-6736(04)16676-2","article-title":"Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial","volume":"364","author":"Grigor","year":"2004","journal-title":"Lancet"},{"key":"10.1136\/annrheumdis-2015-207524_bib17","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1136\/ard.2007.071092","article-title":"Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial)","volume":"66","author":"Verstappen","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2015-207524_bib18","doi-asserted-by":"crossref","first-page":"R254","DOI":"10.1186\/ar4099","article-title":"Adherence to a treat-to-target strategy in early rheumatoid arthritis: results of the DREAM remission induction cohort","volume":"14","author":"Vermeer","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/annrheumdis-2015-207524_bib19","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1136\/ard.2009.123919","article-title":"Treating rheumatoid arthritis to target: recommendations of an international task force","volume":"69","author":"Smolen","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2015-207524_bib20","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/acr.21641","article-title":"2012 update of the 2008 american college of rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis","volume":"64","author":"Singh","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1136\/annrheumdis-2015-207524_bib21","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1136\/ard.2009.126532","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs","volume":"69","author":"Smolen","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2015-207524_bib22","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1136\/annrheumdis-2013-204573","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update","volume":"73","author":"Smolen","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2015-207524_bib23","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s00393-012-1093-6","article-title":"The new 2012 German recommendations for treating rheumatoid arthritis: differences compared to the European standpoint","volume":"72","author":"Wollenhaupt","year":"2013","journal-title":"Z Rheumatol"},{"key":"10.1136\/annrheumdis-2015-207524_bib24","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.reuma.2013.10.006","article-title":"Update of the Mexican College of Rheumatology guidelines for the pharmacologic treatment of rheumatoid arthritis","volume":"10","author":"Cardiel","year":"2014","journal-title":"Reumatol Clin"},{"key":"10.1136\/annrheumdis-2015-207524_bib25","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1136\/ard.2010.149260","article-title":"Association with joint damage and physical functioning of nine composite indices and the 2011 ACR\/EULAR remission criteria in rheumatoid arthritis","volume":"70","author":"Klarenbeek","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2015-207524_bib26","doi-asserted-by":"crossref","first-page":"R56","DOI":"10.1186\/ar4491","article-title":"Remission in rheumatoid arthritis: benefit over low disease activity in patient reported outcomes and costs","volume":"16","author":"Radner","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/annrheumdis-2015-207524_bib27","doi-asserted-by":"crossref","first-page":"285","DOI":"10.3899\/jrheum.090898","article-title":"Does clinical remission lead to normalization of EQ-5D in patients with rheumatoid arthritis and is selection of remission criteria important?","volume":"37","author":"Linde","year":"2010","journal-title":"J Rheumatol"},{"key":"10.1136\/annrheumdis-2015-207524_bib28","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1136\/ard.2011.149765","article-title":"American college of rheumatology\/european league against rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials","volume":"70","author":"Felson","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2015-207524_bib29","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1136\/annrheumdis-2013-204339","article-title":"How low to aim in rheumatoid arthritis? Learning from other disciplines","volume":"73","author":"Porter","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2015-207524_bib30","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1002\/art.38323","article-title":"Review: treat to target in rheumatoid arthritis: fact, fiction, or hypothesis?","volume":"66","author":"Solomon","year":"2014","journal-title":"Arthritis Rheumatol"},{"issue":"Suppl","key":"10.1136\/annrheumdis-2015-207524_bib31","first-page":"S1037","article-title":"Adherence to a Treat-to-Target (T2T) strategy in early rheumatoid arthritis. Is it feasible in daily clinical practice?","volume":"66","author":"Waimann Christian","year":"2014","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2015-207524_bib32","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1136\/ard.2011.154179","article-title":"Treating rheumatoid arthritis to target: multinational recommendations assessment questionnaire","volume":"70","author":"Haraoui","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2015-207524_bib33","unstructured":"Stoffer MA, Schoels M, Smolen JS, et al. Evidence for treating rheumatoid arthritis to target\u2014a systematic literature research informing the treat-to-target task force. Ann Rheum Dis 2015; in press."},{"key":"10.1136\/annrheumdis-2015-207524_bib34","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1136\/ard.2009.123976","article-title":"Evidence for treating rheumatoid arthritis to target: results of a systematic literature search","volume":"69","author":"Schoels","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2015-207524_bib35","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1093\/rheumatology\/ker355","article-title":"Aggressive therapy in patients with early arthritis results in similar outcome compared with conventional care: the STREAM randomized trial","volume":"51","author":"van Eijk","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/annrheumdis-2015-207524_bib36","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1136\/annrheumdis-2011-200274","article-title":"A tight control treatment strategy aiming for remission in early rheumatoid arthritis is more effective than usual care treatment in daily clinical practice: a study of two cohorts in the Dutch Rheumatoid Arthritis Monitoring registry","volume":"71","author":"Schipper","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2015-207524_bib37","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1136\/ard.2008.097683","article-title":"DAS-driven therapy versus routine care in patients with recent-onset active rheumatoid arthritis","volume":"69","author":"Goekoop-Ruiterman","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2015-207524_bib38","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1136\/ard.2010.137695","article-title":"Disease activity score-driven therapy versus routine care in patients with recent-onset active rheumatoid arthritis: data from the GUEPARD trial and ESPOIR cohort","volume":"70","author":"Soubrier","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2015-207524_bib39","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1093\/rheumatology\/ker399","article-title":"Goal-directed therapy for RA in routine practice is associated with improved function in patients with disease duration up to 15 years","volume":"51","author":"Gullick","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/annrheumdis-2015-207524_bib40","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1002\/acr.22010","article-title":"Treating to a target in established active rheumatoid arthritis patients receiving a tumor necrosis factor inhibitor: results from a real-world cluster-randomized adalimumab trial","volume":"65","author":"Pope","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1136\/annrheumdis-2015-207524_bib41","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1136\/annrheumdis-2012-201469","article-title":"The ability of synovitis to predict structural damage in rheumatoid arthritis: a comparative study between clinical examination and ultrasound","volume":"72","author":"Dougados","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"Suppl","key":"10.1136\/annrheumdis-2015-207524_bib42","first-page":"S338","article-title":"Targeting ultrasound remission in early rheumatoid arthritis\u2014results of the Taser study","volume":"65","author":"Dale","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2015-207524_bib43","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1136\/annrheumdis-2012-201821","article-title":"Performance of the 2011 ACR\/EULAR preliminary remission criteria compared with DAS28 remission in unselected patients with rheumatoid arthritis","volume":"72","author":"Thiele","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2015-207524_bib44","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1136\/ard.2010.141523","article-title":"Remission is the goal for cardiovascular risk management in patients with rheumatoid arthritis: a cross-sectional comparative study","volume":"70","author":"Provan","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2015-207524_bib45","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1093\/rheumatology\/kep442","article-title":"Superiority of SDAI over DAS-28 in assessment of remission in rheumatoid arthritis patients using power Doppler ultrasonography as a gold standard","volume":"49","author":"Balsa","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/annrheumdis-2015-207524_bib46","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1136\/annrheumdis-2012-201817","article-title":"In patients with early rheumatoid arthritis, the new ACR\/EULAR definition of remission identifies patients with persistent absence of functional disability and suppression of ultrasonographic synovitis","volume":"72","author":"Sakellariou","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2015-207524_bib47","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1007\/s10067-010-1534-z","article-title":"Paid work is associated with improved health-related quality of life in patients with rheumatoid arthritis","volume":"29","author":"Gronning","year":"2010","journal-title":"Clin Rheumatol"},{"key":"10.1136\/annrheumdis-2015-207524_bib48","doi-asserted-by":"crossref","unstructured":"Stucki G, Cieza A, Geyh S, et al. ICF Core Sets for rheumatoid arthritis. J Rehabil Med 2004;(44 Suppl):87\u201393. doi:10.1080\/16501960410015470","DOI":"10.1080\/16501960410015470"},{"key":"10.1136\/annrheumdis-2015-207524_bib49","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/acr.20021","article-title":"Evidence for predictive validity of remission on long-term outcome in rheumatoid arthritis: A systematic review","volume":"62","author":"van Tuyl","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1136\/annrheumdis-2015-207524_bib50","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1002\/art.38016","article-title":"Sonographic joint assessment in rheumatoid arthritis: associations with clinical joint assessment in remission","volume":"65","author":"Gartner","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2015-207524_bib51","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1136\/annrheumdis-2011-201048","article-title":"After treat-to-target: can a targeted ultrasound initiative improve RA outcomes?","volume":"71","author":"Wakefield","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 2","key":"10.1136\/annrheumdis-2015-207524_bib52","doi-asserted-by":"crossref","first-page":"i89","DOI":"10.1136\/annrheumdis-2011-200797","article-title":"Remission by imaging in rheumatoid arthritis: should this be the ultimate goal?","volume":"71","author":"van der Heijde","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2015-207524_bib53","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.rdc.2005.09.005","article-title":"The definition and measurement of disease modification in inflammatory rheumatic diseases","volume":"32","author":"Aletaha","year":"2006","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1136\/annrheumdis-2015-207524_bib54","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1136\/ard.2005.037333","article-title":"Is DAS28 an appropriate tool to assess remission in rheumatoid arthritis?","volume":"64","author":"Makinen","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2015-207524_bib55","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1136\/ard.2004.034371","article-title":"Comparison of different definitions to classify remission and sustained remission: 1 year TEMPO results","volume":"64","author":"van der Heijde","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2015-207524_bib56","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/art.27740","article-title":"Interleukin-6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: the role of acute-phase reactants","volume":"63","author":"Smolen","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2015-207524_bib57","doi-asserted-by":"crossref","first-page":"3702","DOI":"10.1002\/art.30634","article-title":"Joint damage in rheumatoid arthritis progresses in remission according to the Disease Activity Score in 28 joints and is driven by residual swollen joints","volume":"63","author":"Aletaha","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"Suppl","key":"10.1136\/annrheumdis-2015-207524_bib58","first-page":"S1104","article-title":"Time in remission is important for improvement of physical function in patients with rheumatoid arthritis (RA)","volume":"64","author":"Radner","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"Suppl","key":"10.1136\/annrheumdis-2015-207524_bib59","first-page":"957","article-title":"Being in remission or in low disease activity in rheumatoid arthritis: different meaning with the use of different composite scores","volume":"60","author":"Koevoets","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2015-207524_bib60","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1093\/rheumatology\/kem007","article-title":"Assessing remission in clinical practice","volume":"46","author":"Mierau","year":"2007","journal-title":"Rheumatology"},{"issue":"Suppl 3","key":"10.1136\/annrheumdis-2015-207524_bib61","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1136\/annrheumdis-2013-eular.1369","article-title":"Time to achieve remission and sustained remission for MTX-na\u00efve patients with early RA treated with abatacept plus mtx versus mtx alone in the agree trial","volume":"72","author":"Smolen","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2015-207524_bib62","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1002\/art.21235","article-title":"Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states","volume":"52","author":"Aletaha","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"Suppl 3","key":"10.1136\/annrheumdis-2015-207524_bib63","doi-asserted-by":"crossref","first-page":"iii56","DOI":"10.1136\/ard.2007.078360","article-title":"Tight control in the treatment of rheumatoid arthritis: efficacy and feasibility","volume":"66","author":"Bakker","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2015-207524_bib64","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1136\/annrheumdis-2011-201247","article-title":"Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study","volume":"72","author":"Kavanaugh","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2015-207524_bib65","doi-asserted-by":"crossref","unstructured":"Fleischmann R, van der Heijde D, Koenig AS, et al. How much does Disease Activity Score in 28 joints ESR and CRP calculations underestimate Disease Activity compared with the Simplified Disease Activity Index? Ann Rheum Dis 2014. Published Online First 20 Aug 2014. doi: 10.1136\/annrheumdis-2013-204920http:\/\/dx.doi.org\/10.1136\/annrheumdis-2013-204920","DOI":"10.1136\/annrheumdis-2013-204920"},{"key":"10.1136\/annrheumdis-2015-207524_bib66","unstructured":"Food and Drug Administration. Guidance for Industry\u2014Rheumatoid arthritis: Developing drug products for treatment. Draft Gudance May 2013. http:\/\/www.fdagov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM354468pdf (accessed 5 Oct 2013)."},{"key":"10.1136\/annrheumdis-2015-207524_bib67","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1093\/rheumatology\/31.8.519","article-title":"Prognostic factors for radiographic damage and physical disability in early rheumatoid arthritis. A prospective follow-up study of 147 patients","volume":"31","author":"Van der Heijde","year":"1992","journal-title":"Br J Rheumatol"},{"key":"10.1136\/annrheumdis-2015-207524_bib68","first-page":"425","article-title":"Interrelationship of outcome measures and process variables in early rheumatoid arthritis. A comparison of radiologic damage, physical disability, joint counts, and acute phase reactants","volume":"21","author":"van Leeuwen","year":"1994","journal-title":"J Rheumatol"},{"key":"10.1136\/annrheumdis-2015-207524_bib69","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1002\/art.21678","article-title":"Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate without or with concomitant infliximab. Results from the ASPIRE trial","volume":"54","author":"Smolen","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2015-207524_bib70","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1136\/ard.2010.131201","article-title":"Clinical synovitis in a particular joint is associated with progression of erosions and joint space narrowing in that same joint, but not in patients initially treated with infliximab","volume":"69","author":"Klarenbeek","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2015-207524_bib71","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1136\/ard.2008.091454","article-title":"Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR\/ACR collaborative recommendations","volume":"67","author":"Aletaha","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2015-207524_bib72","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.3899\/jrheum.080182","article-title":"RAPID3 (Routine Assessment of Patient Index Data 3), a rheumatoid arthritis index without formal joint counts for routine care: proposed severity categories compared to disease activity score and clinical disease activity index categories","volume":"35","author":"Pincus","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1136\/annrheumdis-2015-207524_bib73","first-page":"S186","article-title":"Prediction of week 52 treatment response based on a week 12 assessment in rheumatoid arthritis patients receiving certolizumab pegol: comparison of a patient-reported instrument versus physician-based disease activity assessment","volume":"65","author":"Curtis","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2015-207524_bib74","doi-asserted-by":"crossref","unstructured":"Navarro-Compan V, Gherghe AM, Smolen JS, et al. Relationship between disease activity indices and their individual components and radiographic progression in RA: a systematic literature review. Rheumatology 2014 [Epub ahead of print 20 Nov 2014]. doi:10.1093\/rheumatology\/keu413","DOI":"10.1093\/rheumatology\/keu413"},{"key":"10.1136\/annrheumdis-2015-207524_bib75","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1136\/annrheumdis-2013-204021","article-title":"Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNFalpha inhibitors and rituximab","volume":"74","author":"Listing","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2015-207524_bib76","doi-asserted-by":"crossref","first-page":"3502","DOI":"10.1002\/art.34582","article-title":"Mortality rates in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: drug-specific comparisons in the Swedish Biologics Register","volume":"64","author":"Simard","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2015-207524_bib77","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1093\/rheumatology\/keq316","article-title":"Tumour necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review","volume":"50","author":"Westlake","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/annrheumdis-2015-207524_bib78","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/S0140-6736(02)08213-2","article-title":"Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study","volume":"359","author":"Choi","year":"2002","journal-title":"Lancet"},{"key":"10.1136\/annrheumdis-2015-207524_bib79","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1093\/rheumatology\/kep366","article-title":"The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review","volume":"49","author":"Westlake","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/annrheumdis-2015-207524_bib80","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1136\/ard.2005.051144","article-title":"Do patients with older-onset rheumatoid arthritis receive less aggressive treatment?","volume":"65","author":"Tutuncu","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2015-207524_bib81","first-page":"234","article-title":"Safety and efficacy of etanercept treatment in elderly subjects with rheumatoid arthritis","volume":"33","author":"Bathon","year":"2006","journal-title":"J Rheumatol"},{"key":"10.1136\/annrheumdis-2015-207524_bib82","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1093\/rheumatology\/kep291","article-title":"Response of elderly patients with rheumatoid arthritis to methotrexate or TNF inhibitors compared with younger patients","volume":"48","author":"Koller","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/annrheumdis-2015-207524_bib83","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1136\/ard.2010.138693","article-title":"Physical disability in rheumatoid arthritis is associated with cartilage damage rather than bone destruction","volume":"70","author":"Aletaha","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2015-207524_bib84","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1136\/ard.2009.118430","article-title":"Impact of comorbidity on physical function in patients with rheumatoid arthritis","volume":"69","author":"Radner","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2015-207524_bib85","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1093\/rheumatology\/keq334","article-title":"Comorbidity affects all domains of physical function and quality of life in patients with rheumatoid arthritis","volume":"50","author":"Radner","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/annrheumdis-2015-207524_bib86","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1002\/acr.21950","article-title":"Long-term physical functioning and its association with somatic comorbidity and comorbid depression in patients with established rheumatoid arthritis: a longitudinal study","volume":"65","author":"van den Hoek","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1136\/annrheumdis-2015-207524_bib87","doi-asserted-by":"crossref","first-page":"3226","DOI":"10.1002\/art.22943","article-title":"Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients","volume":"56","author":"Aletaha","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2015-207524_bib88","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.3899\/jrheum.111171","article-title":"Timing and magnitude of initial change in disease activity score 28 predicts the likelihood of achieving low disease activity at 1 year in rheumatoid arthritis patients treated with certolizumab pegol: a post-hoc analysis of the RAPID 1 trial","volume":"39","author":"van der Heijde","year":"2012","journal-title":"J Rheumatol"},{"key":"10.1136\/annrheumdis-2015-207524_bib89","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1093\/rheumatology\/kep261","article-title":"Evaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial","volume":"48","author":"Soubrier","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/annrheumdis-2015-207524_bib90","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1002\/art.24433","article-title":"Rheumatoid arthritis joint progression in sustained remission is determined by disease activity levels preceding the period of radiographic assessment","volume":"60","author":"Aletaha","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2015-207524_bib91","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/art.11481","article-title":"Progression of radiologic damage in patients with rheumatoid arthritis in clinical remission","volume":"50","author":"Molenaar","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2015-207524_bib92","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/S0140-6736(12)61811-X","article-title":"Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial","volume":"381","author":"Smolen","year":"2013","journal-title":"Lancet"},{"key":"10.1136\/annrheumdis-2015-207524_bib93","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1093\/rheumatology\/keu338","article-title":"Biologic-free remission of established rheumatoid arthritis after discontinuation of abatacept: a prospective, multicentre, observational study in Japan","volume":"54","author":"Takeuchi","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/annrheumdis-2015-207524_bib94","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1136\/ard.2009.121491","article-title":"Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study","volume":"69","author":"Tanaka","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2015-207524_bib95","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1136\/annrheumdis-2013-204016","article-title":"Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study","volume":"74","author":"Tanaka","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2015-207524_bib96","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1136\/ard.2009.117341","article-title":"Patients with RA in remission on TNF blockers: when and in whom can TNF blocker therapy be stopped?","volume":"69","author":"Saleem","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"4 Suppl 78","key":"10.1136\/annrheumdis-2015-207524_bib97","first-page":"S22","article-title":"Discontinuation of biologics in patients with rheumatoid arthritis","volume":"31","author":"Tanaka","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"10.1136\/annrheumdis-2015-207524_bib98","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1093\/rheumatology\/ker516","article-title":"Sustained drug-free remission in rheumatoid arthritis after DAS-driven or non-DAS-driven therapy: a comparison of two cohort studies","volume":"51","author":"van der Woude","year":"2012","journal-title":"Rheumatology (Oxford)"},{"issue":"Suppl 3","key":"10.1136\/annrheumdis-2015-207524_bib99","first-page":"399","article-title":"Assessing maintenance of remission with reduced dose etanercept plus methotrexate, methotrexate alone, or placebo in patients with early rheumatoid arthritis who achieved remission with etanercept and methotrextate: the PRIZE study","volume":"72","author":"Emery","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2015-207524_bib100","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0140-6736(13)61751-1","article-title":"Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial","volume":"383","author":"Smolen","year":"2014","journal-title":"Lancet"},{"issue":"Suppl 3","key":"10.1136\/annrheumdis-2015-207524_bib101","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1136\/annrheumdis-2013-eular.271","article-title":"Targeting the lowest efficacious dose for rheumatoid arthritis patients in remission: clinical and structural impact of a stepdown strategy trial based on progressive spacing of TNF-blocker injections (STRASS trial)","volume":"72","author":"Fautrel","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2015-207524_bib102","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2013-204317","article-title":"Proposal for a new nomenclature of disease-modifying antirheumatic drugs","volume":"73","author":"Smolen","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2015-207524_bib103","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S0140-6736(96)90535-8","article-title":"Randomised placebo-controlled study of stopping second-line drugs in rheumatoid arthritis","volume":"347","author":"ten Wolde","year":"1996","journal-title":"Lancet"},{"key":"10.1136\/annrheumdis-2015-207524_bib104","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1097\/MAJ.0b013e3181e8bcb0","article-title":"Inadequate therapy behavior is associated to disease flares in patients with rheumatoid arthritis who have achieved remission with disease-modifying antirheumatic drugs","volume":"340","author":"Contreras-Yanez","year":"2010","journal-title":"Am J Med Sci"},{"key":"10.1136\/annrheumdis-2015-207524_bib105","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1093\/rheumatology\/keh116","article-title":"Factors influencing the beliefs of patients with rheumatoid arthritis regarding disease-modifying medication","volume":"43","author":"Goodacre","year":"2004","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/annrheumdis-2015-207524_bib106","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1002\/acr.21657","article-title":"Decision tool to improve the quality of care in rheumatoid arthritis","volume":"64","author":"Fraenkel","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1136\/annrheumdis-2015-207524_bib107","first-page":"2114","article-title":"Compliance to drug treatment of patients with rheumatoid arthritis: a 3 year longitudinal study","volume":"26","author":"Viller","year":"1999","journal-title":"J Rheumatol"},{"key":"10.1136\/annrheumdis-2015-207524_bib108","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1136\/ard.2010.146662","article-title":"Treating rheumatoid arthritis to target: The patient version of the international recommendations","volume":"70","author":"De Wit","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2015-207524_bib109","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1136\/ard.2004.023697","article-title":"EULAR standardised operating procedures for the elaboration, evaluation, dissemination, and implementation of recommendations endorsed by the EULAR standing committees","volume":"63","author":"Dougados","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2015-207524_bib110","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1136\/annrheumdis-2012-202603","article-title":"Inequities in access to biologic and synthetic DMARDs across 46 European countries","volume":"73","author":"Putrik","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2015-207524_bib111","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1136\/annrheumdis-2013-203819","article-title":"Variations in criteria regulating treatment with reimbursed biologic DMARDs across European countries. Are differences related to country's wealth?","volume":"73","author":"Putrik","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2015-207524_bib112","doi-asserted-by":"crossref","first-page":"329","DOI":"10.7326\/0003-4819-156-5-201203060-00004","article-title":"Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial","volume":"156","author":"Bakker","year":"2012","journal-title":"Ann Intern Med"},{"key":"10.1136\/annrheumdis-2015-207524_bib113","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1757-1146-3-8","article-title":"Looking through the \u2018window of opportunity\u2019: is there a new paradigm of podiatry care on the horizon in early rheumatoid arthritis?","volume":"3","author":"Woodburn","year":"2010","journal-title":"J Foot Ankle Res"},{"issue":"4 Suppl 78","key":"10.1136\/annrheumdis-2015-207524_bib114","first-page":"S14","article-title":"The BeSt way of withdrawing biologic agents","volume":"31","author":"Allaart","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"10.1136\/annrheumdis-2015-207524_bib115","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1136\/annrheumdis-2013-203243","article-title":"A two-step treatment strategy trial in patients with early arthritis aimed at achieving remission: the IMPROVED study","volume":"73","author":"Heimans","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2015-207524_bib116","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1136\/annrheumdis-2013-203440","article-title":"Remission induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: a double-blind, randomised, controlled trial in new-onset, treatment-naive, rheumatoid arthritis (the IDEA study)","volume":"73","author":"Nam","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2015-207524_bib117","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1136\/annrheumdis-2013-204882","article-title":"A randomised controlled trial of etanercept and methotrexate to induce remission in early inflammatory arthritis: the EMPIRE trial","volume":"73","author":"Nam","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2015-207524_bib118","doi-asserted-by":"crossref","first-page":"406","DOI":"10.7326\/0003-4819-146-6-200703200-00005","article-title":"Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial","volume":"146","author":"Goekoop-Ruiterman","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1136\/annrheumdis-2015-207524_bib119","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1093\/rheumatology\/keu156","article-title":"Does Russia need a treat-to-target initiative?","volume":"54","author":"Nasonov","year":"2015","journal-title":"Rheumatology (Oxford)"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724019940?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724019940?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/annrheumdis-2015-207524","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T08:29:30Z","timestamp":1739521770000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724019940"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":119,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["S0003496724019940"],"URL":"https:\/\/doi.org\/10.1136\/annrheumdis-2015-207524","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2016,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/annrheumdis-2015-207524","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1136\/annrheumdis-2015-207526","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}